This study aimed to identify the prognostic signature of p16INK4a and related genes in non-small cell lung cancer (NSCLC). Since non-small cell lung cancer shows a poor prognosis, the 5-year survival rate in advanced stages is low. This emphasizes the need to identify more reliable diagnostic biomarkers for the early diagnosis of NSCLC and understand the molecular mechanisms underlying the progression of the disease. The role of P16 in essential cellular pathways are still unknown. Understanding its function and the mechanisms underlying its dysregulation could potentially lead to the development of targeted therapies for certain cancers. To address this, bioinformatics analyses revealed differential expression of genes in lung tumour tissues vs control samples. The interactions among the identified DEGs can help better understand the underlying molecular mechanism of NSCLC. We investigated the correlation between p16INK4a expression and genes involved in the relevant interactive pathways in early-stage NSCLC. These can serve as potential diagnostic and therapeutic biomarkers for NSCLC.
No takes yet. Share an insight, caveat, or question.
Kundadka et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: